

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** Unknown  
**Gender:** Unknown  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Muscle-Specific Kinase (MuSK) Antibody, IgG by CBA-IFA with Reflex to Titer, Serum**

ARUP test code 3006198

MuSK Ab IgG CBA IFA Screen, Serum

**Detected \* (Ref Interval: <1:10)**

MuSK Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: MuSK IgG Ab CBA, Serum, with Rflx

Muscle-specific kinase (MuSK) antibody is found in a subset of patients with myasthenia gravis, primarily those seronegative for muscle acetylcholine receptor (AChR) antibody. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of myasthenia gravis.

This indirect fluorescent antibody cell-based assay (CBA) utilizes muscle-specific kinase (MuSK) transfected cells for the detection of the MuSK IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Muscle-Specific Kinase (MuSK) Antibody Titer, IgG by CBA-IFA, Serum (Reflex for 3006198 MuSK SER Only -not Orderable by Client)**

ARUP test code 3006251

MuSK Ab IgG CBA IFA Titer, Serum

**1:320 \* (Ref Interval: <1:10)**

INTERPRETIVE INFORMATION: MuSK IgG Ab Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Myasthenia Gravis Reflexive Panel**

ARUP test code 3001869

Acetylcholine Binding Antibody

0.2 nmol/L

(Ref Interval: 0.0-0.4)

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: Acetylcholine Binding Ab

Negative ..... 0.0 - 0.4 nmol/L  
Positive ..... 0.5 nmol/L or greater

Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Acetylcholine Blocking Antibody

0 % (Ref Interval: 0-26)

INTERPRETIVE INFORMATION: Acetylcholine Blocking Ab

Negative ..... 0-26 percent blocking  
Indeterminate ..... 27-41 percent blocking  
Positive ..... 42 percent or greater blocking

Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
MuSK Ab IgG CBA IFA Screen, Serum	23-220-119943	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MuSK Ab IgG CBA IFA Titer, Serum	23-220-119943	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Acetylcholine Binding Antibody	23-220-119943	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Acetylcholine Blocking Antibody	23-220-119943	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-220-119943  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 3 of 3 | Printed: 8/9/2023 12:35:55 PM  
4848